Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Karin Tyburski"'
Autor:
Susana M. Campos, Suzanne Berlin, Carolyn N. Krasner, Christin Whalen, Tina Atkinson, Kristin Meegan, Lauren Pereira, Karin Tyburski, Weixiu Lou, Hang Lee, Neil Horowitz, Richard T. Penson
Publikováno v:
Cancer chemotherapy and pharmacology. 89(3)
Temsirolimus, a mTOR inhibitor, and AZD2171, a VEGFR inhibitor, have independently shown activity in patients with gynecological malignancies. Understanding the pivotal role of the PI3K/PTEN/AKT/mTOR pathway in regulating angiogenesis, a phase I stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::857e5ee32f54cfb6ff73892147ab078d
https://pubmed.ncbi.nlm.nih.gov/35142863
https://pubmed.ncbi.nlm.nih.gov/35142863
Autor:
Sara M. Tolaney, Christin Whalen, Gini F. Fleming, Michael J. Birrer, Suzanne E. Dahlberg, Ursula A. Matulonis, Mary K. Buss, Eric P. Winer, Percy Ivy, Joyce F. Liu, Karin Tyburski, Hang Lee
Publikováno v:
European Journal of Cancer. 49:2972-2978
Background Poly(ADP-ribose) polymerase (PARP)-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the effect of combined therapy against PARP and angiogenesis in this population has not been reported. We inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10069d177a9f95b0d357aa38d27149f4
https://doi.org/10.1016/j.ejca.2013.05.020
https://doi.org/10.1016/j.ejca.2013.05.020
Autor:
Maria Roche, Christin Whalen, Suzanne Berlin, Jackie Szymonifka, Karin Tyburski, Ursula A. Matulonis, L. Pereira, Neil S. Horowitz, Susana M. Campos, Richard T. Penson
Publikováno v:
Gynecologic Oncology. 128:215-220
Objective Ovarian cancer is a highly angiogenic tumor and a model for antiangiogenic research. The tyrosine kinase receptor inhibitors target several receptors allowing for the pharmacological disruption of several independent pathways. Sunitinib mal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cd3928ee9ef0f5d7db238d090f7353a
https://doi.org/10.1016/j.ygyno.2012.07.126
https://doi.org/10.1016/j.ygyno.2012.07.126
Autor:
Benjamin D. Humphreys, Emily S. Robinson, Suzanne Berlin, Karin Tyburski, Percy Ivy, Richard T. Penson, Ursula A. Matulonis
Publikováno v:
Clinical Journal of the American Society of Nephrology. 5:477-483
Background and objectives: Hypertension and proteinuria are common but poorly understood renal toxicities of vascular endothelial growth factor (VEGF) receptor signaling pathway inhibitors. In this phase II study of cediranib (AZD2171) for recurrent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b36d93674f8f0f53e457bcd69945f9
https://doi.org/10.2215/cjn.08111109
https://doi.org/10.2215/cjn.08111109
Autor:
Benjamin D. Humphreys, Carolyn N. Krasner, Suzanne Berlin, Ursula A. Matulonis, L. Sullivan, Christin Whalen, Chau Tran, Karin Tyburski, Stephen A. Cannistra, Julie Lee, Percy Ivy, Maria Roche, Anna Berkenblit, Susana M. Campos, Neil S. Horowitz, Richard T. Penson, Corrine Zarwan, Hang Lee, Margaret Hill
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(33)
Purpose Angiogenesis is important for epithelial ovarian cancer (EOC) growth, and blocking angiogenesis can lead to EOC regression. Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56ee1a0db41ab1bb3eb9e65f186fdd9
https://pubmed.ncbi.nlm.nih.gov/19826113
https://pubmed.ncbi.nlm.nih.gov/19826113
Autor:
Richard T. Penson, Gini F. Fleming, Joyce F. Liu, S. P. Ivy, Hang Lee, Ursula A. Matulonis, Christin Whalen, Karin Tyburski, E. Kasparian, Suzanne Berlin, K. Matijevich, EP Winer, Maria Roche, Michael J. Birrer, Sara M. Tolaney
Publikováno v:
Journal of Clinical Oncology. 29:5028-5028
5028 Background: Olaparib is an orally-bioavailable PARP inhibitor with activity as monotherapy in ovarian and breast cancer; cediranib is a multitargeted kinase inhibitor of VEGFR-1/2/3 and c-kit....
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5519cbb410fae075e351b8da8f2eede7
https://doi.org/10.1200/jco.2011.29.15_suppl.5028
https://doi.org/10.1200/jco.2011.29.15_suppl.5028
Autor:
Karin Tyburski, Jin Hwa Lee, Richard T. Penson, Carolyn N. Krasner, Maria Roche, S. P. Ivy, Martin T. King, Ursula A. Matulonis, Suzanne Berlin, C. Lenahan
Publikováno v:
Journal of Clinical Oncology. 26:5501-5501
5501 Background: Angiogenesis is important for ovarian cancer growth; blocking angiogenesis can lead to ovarian cancer regression. Cediranib (AZD2171) is a highly selective and potent oral tyrosine...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fa036c32f1257d333f42b99ad6ca8e1
https://doi.org/10.1200/jco.2008.26.15_suppl.5501
https://doi.org/10.1200/jco.2008.26.15_suppl.5501
Autor:
Ursula A. Matulonis, Maria Roche, Jeffrey G. Supko, Carolyn N. Krasner, Karin Tyburski, Arlan F. Fuller, C. L. Verrill, Michael V. Seiden, O. Tretyakov, Ferdinando D’Amato
Publikováno v:
Journal of Clinical Oncology. 24:5008-5008
5008 Background: A phase III trial (GOG172) demonstrated improved survival for patients with newly diagnosed and optimally debulked ovarian cancer treated with intraperitoneal (ip) cisplatin and paclitaxel (P), given both as a 24 h iv infusion and ip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::554c3c3a48043a09bec500d4c2a826e5
https://doi.org/10.1200/jco.2006.24.18_suppl.5008
https://doi.org/10.1200/jco.2006.24.18_suppl.5008